These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36510488)

  • 41. Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.
    Jiang Y; Liu J; Chen X; Yang W; Jia W; Wu J
    Adv Ther; 2021 Mar; 38(3):1470-1482. PubMed ID: 33582976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center.
    Hardin M; Adanse F; Schexnayder C; Malveaux J; Agbahiwe S
    Fed Pract; 2023 Dec; 40(Suppl 6):S24-S30. PubMed ID: 38812588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention.
    Xiong C; Wu J; Ma Y; Li N; Wang X; Li Y; Ding X
    Diabetes Metab Syndr Obes; 2024; 17():865-880. PubMed ID: 38406269
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
    Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
    Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study.
    Zhou Y; Chen M; Liu L; Chen Z
    Diabetes Metab Syndr Obes; 2022; 15():155-163. PubMed ID: 35046686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.
    Chubb B; Gupta P; Gupta J; Nuhoho S; Kallenbach K; Orme M
    Diabetes Ther; 2021 May; 12(5):1325-1339. PubMed ID: 33723769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
    Nauck MA; Quast DR
    Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.
    Zhong P; Zeng H; Huang M; Fu W; Chen Z
    Endocrine; 2022 Mar; 75(3):718-724. PubMed ID: 34981419
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India.
    Singh AK; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Mar; 16(3):102436. PubMed ID: 35245858
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
    Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
    Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
    [No Abstract]   [Full Text] [Related]  

  • 51. Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues.
    Iqbal AM; Imamudeen N; Basheer A; Menon S; Mohan G; Sani TN; Haroon NN
    Curr Drug Saf; 2021; 16(2):197-206. PubMed ID: 33292155
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity.
    Williams DM; Staff M; Bain SC; Min T
    touchREV Endocrinol; 2022 Mar; 18(1):43-48. PubMed ID: 35975210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
    Crabtree TSJ; Adamson K; Reid H; Barnes D; Sivappriyan S; Bickerton A; Gallen IW; Field BCT; Idris I; Ryder REJ;
    Diabetes Obes Metab; 2022 Jul; 24(7):1398-1401. PubMed ID: 35322528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway.
    Xiang J; Qin L; Zhong J; Xia N; Liang Y
    Diabetes Metab Syndr Obes; 2023; 16():2433-2446. PubMed ID: 37602204
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Christensen RM; Juhl CR; Torekov SS
    Drug Saf; 2019 Aug; 42(8):957-971. PubMed ID: 30972641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
    J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis.
    Dutta D; Kumar M; Shivaprasad KS; Kumar A; Sharma M
    Diabetes Metab Syndr; 2022 Jun; 16(6):102539. PubMed ID: 35709586
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical potential of treatment with semaglutide in type 2 diabetes patients.
    Røder ME
    Drugs Context; 2019; 8():212585. PubMed ID: 31844422
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.